Abstract

Methods, apparatus and systems for providing secondary frequency regulation support to a power transmission system. In some embodiments, a real-time central controller requests current status data from a power distribution network which includes a plurality of distributed energy resources (DERs) and at least one substation battery energy storage system (BESS). The real-time central controller also receives an Automatic Generation Control (AGC) signal from a system operator, calculates a mismatch value, determines that the absolute value of the mismatch value is greater than a predetermined tolerance, and sets an optimal setpoint value for each of the plurality of DERs and an optimal setpoint value for the BESS. In some implementations, the real-time central controller next transmits a secondary frequency response that includes the optimal setpoint values to each of the plurality of DERs and the optimal setpoint value to the at least one BESS, thus providing secondary frequency regulation support.

IPC Classes  ?

• H02J 3/24 - Arrangements for preventing or reducing oscillations of power in networks
• H02J 3/32 - Arrangements for balancing the load in a network by storage of energy using batteries with converting means
• H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers
• H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
• H02J 13/00 - Circuit arrangements for providing remote indication of network conditions, e.g. an instantaneous record of the open or closed condition of each circuitbreaker in the networkCircuit arrangements for providing remote control of switching means in a power distribution network, e.g. switching in and out of current consumers by using a pulse code signal carried by the network

Abstract

Disclosed herein are α7 integrin modulatory agents and methods of using such to treat muscular disorders, disease, degeneration, and/or muscular dystrophy. The methods include administering an effective amount of an α7 integrin modulatory agent to the subject with a muscular disorder, disease, degeneration, and/or dystrophy, wherein the α7 integrin modulatory agent increases α7 integrin expression or activity as compared to α7 integrin expression or activity prior to treatment, thereby treating the subject. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7 integrin expression by use of the disclosed α7 integrin modulatory agents. Methods of preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Abstract

Herein provided is a new potato variety designated ‘UNR-01’ as well as the tubers, seeds, plants, plant parts, and derivatives of the new potato variety ‘UNR-01’. This transgenic variety was generated using CRISPR-Cas9 and deleting a portion of the StMYB93 (PGSC0003DMG400006408) gene. This transgenic variety has a sprout suppressed phenotype that results in a longer storage life in cold storage conditions without the application of sprout-inhibiting chemicals. These potatoes were not impacted in reduced sugar levels, wound healing capacities, and native periderm suberin content. Also provided are tissue cultures of the new potato variety ‘UNR-01’ and the plants regenerated therefrom. Methods for producing potato plants by crossing the new potato variety ‘UNR-01’ with itself or another potato variety and plants produced by such methods are also provided. ‘UNR-01’ potatoes exhibit suppressed sprouting and longer storage life in cold storage conditions without the application of sprout-inhibiting chemicals.

IPC Classes  ?

• A01H 6/82 - Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
• A01H 5/06 - Roots

Abstract

Systems and methods are provided for creating and using digital models of real-world systems with a learning or data assimilation method. The systems and methods may be used to create and/or use a quantifiable model of a real-world system formed of a variety of sub-systems. and create and/or manage or quantified error or bias of the model. The learning network may be used to jointly estimate model parameters, dynamic input loads, and the statistical characteristics of the prediction error that includes the effects of modeling error and measurement noise. The learning network may be an adaptive recursive Bayesian inference framework. The prediction error may be of the form of a non-stationary Gaussian process with unknown and time-variant mean vector and covariance matrix to be estimated.

IPC Classes  ?

• G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators
• G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric

Abstract

A modular, hybrid robotic system for inspecting a structure can include a rigid frame, a modular propulsion system associated with a flight mode of the robotic system, the propulsion system comprising a plurality of propellers, a modular locomotion system associated with a climbing and/or driving mode of the robotic system, the locomotion system comprising a plurality of wheel systems, each wheel system comprising a support leg coupled to the rigid frame and at least one wheel coupled to the support leg, and a modular floating system associated with a swimming mode of the robotic system. In operation, all or some of the components of the propulsion system, locomotion system, and floating system can be included depending on a desired function.

IPC Classes  ?

• B64U 10/16 - Flying platforms with five or more distinct rotor axes, e.g. octocopters
• B64U 50/13 - Propulsion using external fans or propellers
• B64U 50/30 - Supply or distribution of electrical power
• B64U 101/26 - UAVs specially adapted for particular uses or applications for manufacturing or servicing for manufacturing, inspections or repairs

Goods & Services

Promoting and managing innovation initiatives in the fields of energy, technology, critical minerals, mining, material processing, energy storage, recycling, and circular economy; Providing public policy information in the fields of energy, technology, critical minerals, mining, material processing, energy storage, recycling, workforce development, economic development, and circular economy; Business networking Venture capital services, namely, providing financing to emerging and start-up companies; Fundraising and financing services for the benefit of local economies, workforces, and educational research Organizing and conducting of in-person events and forums in the fields of energy, technology, critical minerals, mining, material processing, energy storage, recycling, workforce development, economic development, and circular economy Research and development support services in the fields of energy, technology, critical minerals, mining, material processing, energy storage, recycling, and circular economy

Goods & Services

Promoting and managing innovation initiatives in the fields of energy, technology, critical minerals, mining, material processing, energy storage, recycling, and circular economy; Providing public policy information in the fields of energy, technology, critical minerals, mining, material processing, energy storage, recycling, workforce development, economic development, and circular economy; Business networking Venture capital services, namely, providing financing to emerging and start-up companies; Fundraising and financing services for the benefit of local economies, workforces, and educational research Organizing and conducting of in-person events and forums in the fields of energy, technology, critical minerals, mining, material processing, energy storage, recycling, workforce development, economic development, and circular economy Research and development support services in the fields of energy, technology, critical minerals, mining, material processing, energy storage, recycling, and circular economy

Abstract

Disclosed herein are embodiments of a method for recovering metal from electrode active materials. In particular embodiments, the method comprises recovering at least one metal from a lithium-ion battery (LIB), wherein a lixiviant is used without the need for an extraneous reducing agent. In particular aspects of the disclosure, a particular solid-to-liquid ratio of the electrode active material and lixiviant is used to promote selective recovery of lithium. In yet other aspects, reaction temperature and/or stirring speeds can be used to improve selective lithium recovery and efficiency using lixiviants disclosed herein.

IPC Classes  ?

• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• C22B 3/44 - Treatment or purification of solutions, e.g. obtained by leaching by chemical processes
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 26/12 - Obtaining lithium

Abstract

Disclosed herein are optoelectronically dynamic elements (e.g., windows, films, lenses, flat-panel displays, polymer-based electronics, thin film photovoltaics, glass doors, tools/devices used in X-ray diffraction and scanning electron microscopy analysis, among others) comprising non-aqueous zinc-based electrolytes that facilitate reversible zinc electrodeposition on the element. The disclosed non-aqueous zinc-based electrolytes are used in combination with a transparent working electrode and a counter electrode and facilitate depositing layers of zinc on the transparent working electrode so as to rapidly form an opaque zinc-containing coating on the working electrode upon application of a suitable voltage. The opaque zinc-containing coating can be rapidly stripped from the working electrode transitioning it back to a transparent state upon application of a suitable voltage. Also disclosed are methods of making and using the disclosed non-aqueous zinc-based electrolyte and elements described herein.

IPC Classes  ?

• G02F 1/155 - Electrodes
• G02F 1/163 - Operation of electrochromic cells, e.g. electrodeposition cellsCircuit arrangements therefor

Abstract

Disclosed herein are optoelectronically dynamic elements (e.g., windows, films, lenses, flat-panel displays, polymer-based electronics, thin film photovoltaics, glass doors, tools/devices used in X-ray diffraction and scanning electron microscopy analysis, among others) comprising non-aqueous zinc-based electrolytes that facilitate reversible zinc electrodeposition on the element. The disclosed non-aqueous zinc-based electrolytes are used in combination with a transparent working electrode and a counter electrode and facilitate depositing layers of zinc on the transparent working electrode so as to rapidly form an opaque zinc-containing coating on the working electrode upon application of a suitable voltage. The opaque zinc-containing coating can be rapidly stripped from the working electrode transitioning it back to a transparent state upon application of a suitable voltage. Also disclosed are methods of making and using the disclosed non-aqueous zinc-based electrolyte and elements described herein.

IPC Classes  ?

• G02F 1/1506 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect based on electrodeposition, e.g. electrolytic deposition of an inorganic material on or close to an electrode
• G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material

Abstract

The present disclosure provides genetically edited or modified plants of the genus Sorghum and methods of producing genetically edited or modified plants of the genus Sorghum using, e.g., a CRISPR/Cas9 gene editing tool. In some embodiments, the genetic modifications are directed to genes of the Inhibition of Alien Pollen (IAP) locus to modulate cross-compatibility of the plants with other species of Sorghum.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Disclosed herein are embodiments of a polycyclic aromatic electroactive material for use in electrochemical devices (e.g., electrodes, electrochemical cells, and the like) that is capable of intercalating multivalent ions. Methods of making electrochemical devices are disclosed, along with methods of making the polycyclic aromatic electroactive material and uses thereof.

IPC Classes  ?

• H10K 85/60 - Organic compounds having low molecular weight
• C07C 15/20 - Polycyclic condensed hydrocarbons
• H10K 85/10 - Organic polymers or oligomers

Abstract

An improved data mapping method for roadside LiDAR sensor data which is accurate, inexpensive to implement and that provides data which is easy to use and/or interpret. In an embodiment a computer processor running Geographic Information System (GIS)-based software obtains geographic coordinates data for a roadway section with objects within a detection range of a roadside LiDAR sensor system. Next, the computer processor receives roadside LiDAR sensor data expressed as LiDAR cartesian coordinates data for the roadway section, receives selection by a user of a plurality of reference objects defined by the geographic coordinates data and by the LiDAR cartesian coordinates data, calculates transition matrixes for transforming the LiDAR cartesian coordinates data into geographic coordinates data, and converts the LiDAR cartesian coordinates data into LiDAR geographic coordinates data using the transition matrixes. In some implementations, the computer processor transmits the LiDAR geographic coordinate data to a user computer for analysis, and/or displays the LiDAR geographic coordinate data of the roadway section on a display screen.

IPC Classes  ?

• G01S 17/89 - Lidar systems, specially adapted for specific applications for mapping or imaging
• G08G 1/07 - Controlling traffic signals

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/864 - Parvoviral vectors

Abstract

The present disclosure relates to nucleic acid regulatory cassettes useful for the expression of transgene payloads in specific muscle tissues. Also included in the present disclosure are vectors, including adeno-associated virus (AAV) vectors, comprising the regulatory cassettes of the invention, as well as compositions and methods of treating genetic diseases or disorders also comprising said regulatory cassettes.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/864 - Parvoviral vectors
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

A photovoltaic device includes a substrate, a first electrode on a surface of the substrate, a second electrode, and a first photoactive layer between the first electrode and the second electrode. The first photoactive layer includes graphene nanoribbons (GNRs).

IPC Classes  ?

• H10K 30/50 - Photovoltaic [PV] devices
• H10K 30/20 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising organic-organic junctions, e.g. donor-acceptor junctions
• H10K 85/20 - Carbon compounds, e.g. carbon nanotubes or fullerenes

Abstract

Disclosed herein are dithiol-based polymers and cyclic compounds that can be formed therefrom. The cyclic compounds also can be used to regenerate recycled polymers. Methods for making native and recycled polymers are described herein, along with methods for using the compounds of the present disclosure to provide crosslinked "vitrimer"-like products.

IPC Classes  ?

• C07C 321/14 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
• C08G 59/66 - Mercaptans
• C08G 75/02 - Polythioethers
• C07C 321/24 - Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
• C07C 319/18 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by addition of thiols to unsaturated compounds

Abstract

Methods, systems and apparatus for providing timely and accurate estimates of the location and rate-of-spread of a wildfire. In some embodiments, a processor of a user device receives user defined polygon data estimating a perimeter of a wildfire and generates ellipse data fitting the polygon data. The processor also receives radar reflectivity data via a communication device from at least one weather radar, then determines, based on the radar reflectivity data and the ellipse data, local maxima data and a plurality of fire points, and then generates, based on the plurality of fire points, an updated estimate of the perimeter of the wildfire. In some implementations, the processor of the user device may also transmit the updated estimate of the perimeter of the wildfire to a wildfire update website.

IPC Classes  ?

• G01S 17/95 - Lidar systems, specially adapted for specific applications for meteorological use

Abstract

Methods, systems and apparatus are disclosed for conducting background filtering on LiDAR sensor data. In some embodiments, a computer processor of a computer receives raw LiDAR sensor data from a roadside LiDAR sensor, decodes the raw LiDAR sensor data into 3D distance data, azimuth angle data and vertical angle data, and then generates a background table of datapoints utilizing the azimuth angle data and elevation data. The process also includes the computer processor comparing the 3D distance data to the datapoints of the background table, determining, based on the comparisons, static background object datapoints, and discarding the static background object datapoints. In implementations, the computer processor determines target datapoints based on the comparisons, and then stores the target datapoints in a storage device.

IPC Classes  ?

• G08G 1/01 - Detecting movement of traffic to be counted or controlled

Abstract

BurkholderiaBurkholderiaB. thailandensisBurkholderiaBurkholderia CPS isolated and purified by the disclosed method.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C12N 1/20 - BacteriaCulture media therefor
• A61P 31/04 - Antibacterial agents
• A61K 39/02 - Bacterial antigens

Abstract

The present invention is directed to a new class of pH tunable electrolytes and related compositions that facilitate the reversible electrodeposition of zinc, bismuth and copper metals on transparent conducting electrodes. These electrolytes are relevant to and are used to provide dynamic windows and other technologies that contain an optoelectronically switchable material.

IPC Classes  ?

• E06B 9/24 - Screens or other constructions affording protection against light, especially against sunshineSimilar screens for privacy or appearance
• G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect
• G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material
• G02F 1/155 - Electrodes
• G09G 3/38 - Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix by control of light from an independent source using electrochromic devices
• H01G 9/20 - Light-sensitive devices

Abstract

A method for automatic, image-based detection of abnormalities in a patient's cervix is disclosed. In an embodiment, a Cervitude Imaging System (CIS) processor of a CIS device illuminates a light source affixed to a distal end of a probe housing, receives cervical image data of the patient from a camera affixed to the distal end of the probe housing, generates a reconstructed image that includes reduced specular reflections, and segments the reconstructed image into at least one region of interest (ROI). The process also includes the CIS processor transmitting the reconstructed image comprising the at least one ROI to at least one of a host system and an input/output device.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/11 - Region-based segmentation
• G06T 7/00 - Image analysis
• G06T 7/136 - SegmentationEdge detection involving thresholding

Abstract

The disclosure relates to methods and compositions for inhibiting the expression of the DUX4 gene in skeletal muscle cells. In some aspects, the invention includes a CRISPR interference platform that directs an epigenetic regulator to the DUX4 locus. In some aspects, methods described by the disclosure are useful in modulating DUX4 expression for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Goods & Services

(1) Transmission of sound, video and information from web cams or video cameras, all featuring live or recorded materials. (2) Design of wireless computer networks for others; design and development of wireless computer networks; planning and development of electronic communications networks.

Goods & Services

Transmission of sound, video and information from web cams or video cameras, all featuring live or recorded materials. Design of wireless computer networks for others; design and development of wireless computer networks; planning and development of electronic communications networks.

Abstract

Methods, systems and apparatus for compensating vision loss for a patient. In some embodiments, a computer processor receives vision loss data associated with a vision loss region of an eye of a patient from a head mounted display (HMD) device worn by the patient, generates a parameterized perceptual loss model, and then generates inverse data to correct for color loss, contrast and luminance desaturation, and visual rotational and spatial distortion suffered by the eye of the patient. The computer processor then transmits the inverse data to the HMD device being worn by the patient for use in correcting the visual rotational and spatial distortion loss of the eye of the patient.

IPC Classes  ?

• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

A method, apparatus and system for providing an estimate of the level of compaction of a layer of pavement materials in real time. In some embodiments, a Retrofit Intelligent Compaction Analyzer (RICA) processor of a RICA device receives vibrational energy data from a sensor module which corresponds to impact responses of a drum of a roller machine during compaction of a pavement material over a section of pavement. The RICA processor also receives temperature data from the sensor module, determines an estimated level of compaction in real time of the section of pavement based on the vibrational energy data, pavement material characteristics data and the temperature data, and displays a density level percentage of the section of pavement on a display device for viewing by an operator of the roller machine.

IPC Classes  ?

• G01N 3/00 - Investigating strength properties of solid materials by application of mechanical stress

Goods & Services

Transmission of sound, video and information from web cams or video cameras, all featuring live or recorded materials Design of wireless computer networks for others; design and development of wireless computer networks; planning and development of electronic communications networks

Abstract

Disclosed herein are embodiments of polycyclic aromatic compounds and methods of making and using the same. Various different types of polycyclic ring systems are disclosed, including, but not limited to, polymeric aromatic compounds (e.g., nanographene compounds), pentacene-like compounds, chiral aromatic compounds, asymmetric arene compounds formed from naphthalene-, anthracene-, phenanthrene-, and pyrene-based starting compounds, and dimerized aromatic compounds. Also disclosed herein are novel benzannulation-based methods for making the disclosed polycyclic aromatic compounds.

IPC Classes  ?

• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C08F 132/08 - Homopolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system having condensed rings
• C07C 323/21 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
• C07D 333/10 - Thiophene
• C07D 333/76 - Dibenzothiophenes
• C07D 213/06 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
• C07B 37/10 - Cyclisation

Abstract

Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a verterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a B. burgdorferi- associated condition, such as Lyme disease. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a B. burgdorferi- associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by B. burgdorferi, such as Lyme disease.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody

Abstract

Streptococcus PneumoniaeStreptococcus PneumoniaeStreptococcus Pneumoniae infections.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/12 - Cyclic peptides
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/424 - Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/04 - Antibacterial agents

Abstract

The present disclosure is directed toward an electrodeposition-based dynamic glass element comprising an electrolyte that includes an aqueous solvent and an additive, wherein the electrolyte is stable over a temperature range that is greater than the stable temperature range of the aqueous solvent alone. In some embodiments, the freezing point of the electrolyte is lowered by its inclusion of the additive. Additives suitable for use in accordance with the present disclosure include alcohols, metal salts, sugars, cryoprotectants, and the like. In some cases, the freezing point of the aqueous-solvent-based electrolyte is lowered from 0° C. to −40° C. by virtue of the inclusion of the additive. In some cases, the maximum stable temperature of the electrolyte is increased from 100° C. to 110° C. by virtue of the inclusion of the additive.

IPC Classes  ?

• G02F 1/1506 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect based on electrodeposition, e.g. electrolytic deposition of an inorganic material on or close to an electrode
• G02F 1/155 - Electrodes

Abstract

The present invention relates to methods and compositions comprising a miR-10a-5p or miR-10b-5p mimic for treatment of gastrointestinal motility disorders, obesity and diabetes.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

Abstract

Provided herein are screening methods to select catalysts having a desired set of target properties from a reference catalyst, and catalysts so obtained, as well as related catalysts material, composition, methods and systems.

IPC Classes  ?

• G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• B01J 23/745 - Iron
• B01J 35/02 - Solids

Abstract

Provided herein are screening methods to select catalysts having a desired set of target properties from a reference catalyst, and catalysts so obtained, as well as related catalysts material, composition, methods and systems.

IPC Classes  ?

• G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
• G16C 60/00 - Computational materials science, i.e. ICT specially adapted for investigating the physical or chemical properties of materials or phenomena associated with their design, synthesis, processing, characterisation or utilisation
• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• G06F 30/20 - Design optimisation, verification or simulation
• B01J 23/745 - Iron
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 23/80 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with zinc, cadmium or mercury

Abstract

Disclosed is an apparatus, such as a soil sensor, to collect a plurality of measurements, including a soil moisture measurement and a baseline measurement for comparison with the soil moisture measurement. Also disclosed is a method of sensing soil moisture in two or more different soil locations using two or more Internet of Things (IoT) soil moisture sensors.

IPC Classes  ?

• G01N 27/22 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
• G08C 17/02 - Arrangements for transmitting signals characterised by the use of a wireless electrical link using a radio link
• G01N 33/24 - Earth materials

Abstract

Disclosed are methods of treating metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH), and Type II diabetes. In some examples, the method includes administration of an effective amount of a (pro)renin receptor (PRR) antagonist to a subject in need thereof, such as a patient at risk of acquiring or afflicted with NAFLD, NASH and/or Type II diabetes, to prevent, inhibit, and/or reduce one or more signs or symptoms associated with NAFLD, NASH and/or Type II diabetes, such as by reducing the severity of liver steatosis.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Disclosed herein are embodiments of methods that utilize dry adhesion tuning of a composite structure to adhere substrates. In some embodiments, the disclosed methods utilize dry adhesion between a composite structure and a substrate and further dynamically control the resulting dry adhesion strength through a heating step, which facilitates rigidity tuning of a core component of the composite structure and/or facilitates thermal control of the interface between the substrate and the composite structure. Also disclosed herein are array devices and other products comprising the disclosed composite structures.

IPC Classes  ?

• B32B 37/12 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by using adhesives
• B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties

Abstract

The present invention relates to the discovery that Forskolin can be used to treat Parkinson's disease (PD) in subjects in need thereof. In certain embodiments, the invention provides a method of treating PD, wherein a therapeutically effective amount of Forskolin is administered to a subject via intranasal or intrapulmonary routes. In other embodiments, the subject is further administered a therapeutically effective amount of Noopept. In yet other embodiments, the method reverses damage to the subject's brain caused by PD and promotes growth of new neurons.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs

Abstract

Disclosed herein are embodiments of polycyclic aromatic compounds and methods of making and using the same. Various different types of polycyclic ring systems are disclosed, including, but not limited to, polymeric aromatic compounds (e.g., nanographene compounds), pentacene-like compounds, chiral aromatic compounds, asymmetric arene compounds formed from naphthalene-, anthracene-, phenanthrene-, and pyrene-based starting compounds, and dimerized aromatic compounds. Also disclosed herein are novel benzannulation-based methods for making the disclosed polycyclic aromatic compounds.

IPC Classes  ?

• C07C 323/21 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C07D 333/10 - Thiophene
• C07D 333/76 - Dibenzothiophenes

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Disclosed herein are embodiments of a molybdate-based composition and a conversion coating obtained therefrom that can replace conventional and toxic chromate-based conversion coatings in a variety of applications and industries. The molybdate-based composition provides conversion coatings that exhibit anodic inhibition and rapid repassivation when applied to objects, such as metal -based objects, and do not contain hexavalent chromium. The molybdate-based composition and conversion coating can be used to reduce corrosion. Embodiments of methods of protecting objects, such as metal surfaces, with the molybdate-based conversion coating also are disclosed.

IPC Classes  ?

• C23C 22/44 - Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions using aqueous acidic solutions with pH < 6 containing molybdates, tungstates or vanadates containing also fluorides or complex fluorides

Abstract

The present disclosure is directed toward an electrodeposition-based dynamic glass element comprising an electrolyte that includes an aqueous solvent and an additive, wherein the electrolyte is stable over a temperature range that is greater than the stable temperature range of the aqueous solvent alone. In some embodiments, the freezing point of the electrolyte is lowered by its inclusion of the additive. Additives suitable for use in accordance with the present disclosure include alcohols, metal salts, sugars, cryoprotectants, and the like. In some cases, the freezing point of the aqueous-solvent- based electrolyte is lowered from 0 °C to -40 °C by virtue of the inclusion of the additive. In some cases, the maximum stable temperature of the electrolyte is increased from 100 °C to 110 °C by virtue of the inclusion of the additive.

IPC Classes  ?

• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect
• G02B 1/06 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of fluids in transparent cells
• G02B 26/02 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the intensity of light

Abstract

Burkholderia pseudomalleiBurkholderia malleiB. pseudomallei B. pseudomallei or B. malleiB. pseudomallei or B. mallei. Also disclosed are methods for treating a subject having melioidosis or glanders.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/02 - Bacterial antigens
• A61P 31/04 - Antibacterial agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A system for determining snowpack characteristics includes a weight plate, at least one pressure sensor, and an inert plate surrounding the weight plate. The weight plate and the inert plate can be spaced apart from one another, and, in some cases, the weight plate has a perimeter and the inert plate surrounds the entirety of the perimeter of the weight plate with a gap formed therebetween.

IPC Classes  ?

• G01W 1/14 - Rainfall or precipitation gauges
• G01D 21/02 - Measuring two or more variables by means not covered by a single other subclass
• G01N 5/00 - Analysing materials by weighing, e.g. weighing small particles separated from a gas or liquid
• G01G 17/04 - Apparatus for, or methods of, weighing material of special form or property for weighing fluids, e.g. gases, pastes

Abstract

3 photosynthesis during the subsequent day in a plant cell, thereby altering CAM in the plant cell. Also disclosed herein are isolated polynucleotide sequences, transformation vectors, transgenic plant cells, plant part, and plants. The disclosed methods and compositions can be used to improve the water-use efficiency and drought tolerance and durability of plants, such as in plants in arid environments, and also enhance the ability of plants to perform.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Abstract

Disclosed herein are a module, system and technique to enhance end bearing stiffness of pile/drilled shafts. In particular, methods, systems and loading modules which account for tip resistance in overall pile/shaft capacity are provided which increase the stiffness of the bearing soil. The techniques utilize a mechanical system to preload the soil under the shaft tip, thus allowing the users to confidently account for the gained resistance at an acceptable level of movement. Each shaft/pile is preloaded during construction to verify its load carrying capability.

IPC Classes  ?

• E02D 5/38 - Concrete or concrete-like piles cast in position making by use of mould-pipes or other moulds
• E02D 15/04 - Placing concrete in mould-pipes, pile tubes, boreholes, or narrow shafts
• E02D 5/66 - Mould-pipes or other moulds

Abstract

A porewater pressure dissipater is disclosed. In one example, a disclosed dissipater includes aggregate; a cylindrical receptacle for receiving the aggregate; a plate having a top surface and a bottom surface and one or more openings transcending from the top surface to the bottom surface wherein the plate secures and compacts the aggregate in the cylindrical receptacle; and one or more access tubes coupled to the top surface of the plate wherein the one or more access tubes are positioned over the one or more openings thereby forming a passageway to the cylindrical receptacle. The disclosed dissipater allows piles and shafts to be embedded at the optimum depth without concerns of liquefaction.

IPC Classes  ?

• E02D 5/30 - Prefabricated piles made of concrete or reinforced concrete or made of steel and concrete
• E02D 31/02 - Protective arrangements for foundations or foundation structuresGround foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution against ground humidity or ground water
• E02D 31/12 - Protective arrangements for foundations or foundation structuresGround foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution against soil pressure or hydraulic pressure against upward hydraulic pressure
• E02D 3/00 - Improving or preserving soil or rock, e.g. preserving permafrost soil
• E02D 5/34 - Concrete or concrete-like piles cast in position
• E02D 15/04 - Placing concrete in mould-pipes, pile tubes, boreholes, or narrow shafts
• E02D 27/12 - Pile foundations
• E02D 27/34 - Foundations for sinking or earthquake territories

Abstract

One aspect of the invention provides an automotive electronic control unit (ECU) including: an application processor; and one or more co-processors communicatively coupled to the application processor. The one or more co-processors are configured to: receive data from the application processor; encrypt the data received from the application processor; process the encrypted data to detect faults and generate secure data that is encrypted and free from faults; and communicate the secure data to the application processor.

IPC Classes  ?

• H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
• G06F 11/16 - Error detection or correction of the data by redundancy in hardware
• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
• B60R 16/023 - Electric or fluid circuits specially adapted for vehicles and not otherwise provided forArrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for electric for transmission of signals between vehicle parts or subsystems
• G06F 11/18 - Error detection or correction of the data by redundancy in hardware using passive fault-masking of the redundant circuits, e.g. by quadding or by majority decision circuits

Abstract

Implementations of diagnostic systems for detecting a bacterial infection in a subject may include: a device for receiving a sample of a bodily fluid from a subject, a chemical composition configured to react with one or more antibodies in the bodily fluid, and an indicator configured to indicate or respond to a product of the reaction of the chemical composition with one or more antibodies in a bodily fluid received into the device. The antibodies may be produced in response to one or more conserved antigens from one or more bacteria identified as potentially associated with at least one disease associated with the subject. The device may be coated with the chemical composition. The indicator may be configured to communicate to a user of the system a presence or an absence of the one or more antibodies in the bodily fluid.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/534 - Production of labelled immunochemicals with radioactive label
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Disclosed herein are methods of altering tissue succulence in plants. In some examples, a disclosed method includes overexpressing a modified helix-loop-helix transcription factor CEB1 in a plant cell, thereby altering plant succulence. The disclosed methods can be used to improve the drought and salinity tolerance of plants, such as in plants in arid or saline environments, and also enhance the ability of plants to perform. Also disclosed are CEB1 nucleic acids and transgenic plants containing such nucleic acids.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 38/05 - Dipeptides
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4164 - 1,3-Diazoles
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Methods of labeling, identifying and differentiating microorganisms using functionalized Buckyballs are provided herein. The invention further provides methods for imaging or inhibiting gene expression using functionalized Buckyballs of the invention. The invention also provides a system for labeling, identifying and differentiating microorganisms.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12Q 1/6841 - In situ hybridisation

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 38/05 - Dipeptides
• A61K 31/4164 - 1,3-Diazoles

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

In one embodiment, the present disclosure provides a target or mold having one or more support arms coupled to a substrate. The support arm can be used in handling or positioning a target. In another embodiment, the present disclosure provides target molds, targets produced using such molds, and a method for producing the targets and molds. In various implementations, the targets are formed in a number of disclosed shapes, including a funnel cone, a funnel cone having an extended neck, those having Gaussian-profile, a cup, a target having embedded metal slugs, metal dotted foils, wedges, metal stacks, a Winston collector having a hemispherical apex, and a Winston collector having an apex aperture. In yet another embodiment, the present disclosure provides a target mounting and alignment system.

IPC Classes  ?

• H05G 2/00 - Apparatus or processes specially adapted for producing X-rays, not involving X-ray tubes, e.g. involving generation of a plasma
• B25J 11/00 - Manipulators not otherwise provided for
• F16M 13/02 - Other supports for positioning apparatus or articlesMeans for steadying hand-held apparatus or articles for supporting on, or attaching to, an object, e.g. tree, gate, window-frame, cycle
• H05H 1/46 - Generating plasma using applied electromagnetic fields, e.g. high frequency or microwave energy
• H01J 40/16 - Photoelectric discharge tubes not involving the ionisation of a gas having photo-emissive cathode, e.g. alkaline photoelectric cell
• H05H 6/00 - Targets for producing nuclear reactions

Abstract

Disclosed herein are embodiments of composites and compositions that can be used for therapeutic applications in vivo and/or in vitro. The disclosed composites can comprise cores having magnetic nanoparticles, quantum dots, or combinations thereof and zwitterionic polymeric coatings that facilitate solubility and bioconjugation. The compositions disclosed herein can comprise the composites and one or more biomolecules, drugs, or combinations thereof. Also disclosed herein are methods of making the composites, composite components, and methods of making quantum dots for use in the composites.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 49/00 - Preparations for testing in vivo
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Magnetic wheels, steel-climbing robots, and methods and systems for inspection of steel structures are disclosed, along with variations, alternatives, and modifications. A disclosed magnetic wheel has radially oriented rare-earth magnets disposed in an elastomeric wheel body. The magnets are disposed in circumferential rings about the wheel's axis. Neighboring rings have azimuthally staggered patterns. A steel-climbing robot employing such magnetic wheels is capable of traversing steel structures including obstacles, discontinuities, 90° joints, and rough surfaces.

IPC Classes  ?

• B60C 11/00 - Tyre tread bandsTread patternsAnti-skid inserts
• B60C 11/14 - Anti-skid inserts, e.g. vulcanised into the tread band
• B60C 11/16 - Anti-skid inserts, e.g. vulcanised into the tread band of plug form, e.g. made from metal, textile

Abstract

A method includes determining an angular speed of a transceiver of a first movable node based at least in part on a confidence level. The confidence level is representative of a probability of discovering a second node. The method further includes moving the transceiver at the angular speed, transmitting a beacon signal with the transceiver, and receiving a signal with the transceiver from the second node when a line-of-sight alignment between the transceiver and the second node is established. The method further includes ceasing motion of the transceiver at the angular speed. Another method includes at a first node, receiving information of a velocity, a direction of motion, and a transceiver orientation of a second node when a line-of-sight alignment is established. The method further includes moving the transceiver of the first node at an angular velocity direction in azimuthal and elevational planes to maintain the line-of-sight alignment.

IPC Classes  ?

• H04W 64/00 - Locating users or terminals for network management purposes, e.g. mobility management
• B64C 39/02 - Aircraft not otherwise provided for characterised by special use
• G08G 5/00 - Traffic control systems for aircraft
• H04B 7/00 - Radio transmission systems, i.e. using radiation field
• H04B 7/06 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas at the transmitting station
• H04B 7/185 - Space-based or airborne stations

Abstract

A system for determining snowpack characteristics includes a weight plate, at least one pressure sensor, and an inert plate surrounding the weight plate. The weight plate and the inert plate can be spaced apart from one another, and, in some cases, the weight plate has a perimeter and the inert plate surrounds the entirety of the perimeter of the weight plate with a gap formed therebetween.

IPC Classes  ?

• G01N 5/00 - Analysing materials by weighing, e.g. weighing small particles separated from a gas or liquid
• G01D 21/02 - Measuring two or more variables by means not covered by a single other subclass
• G01L 1/00 - Measuring force or stress, in general
• G01G 3/12 - Weighing apparatus characterised by the use of elastically-deformable members, e.g. spring balances wherein the weighing element is in the form of a solid body stressed by pressure or tension during weighing

Abstract

Disclosed herein are embodiments of engineered geothermal systems (EGS). Also disclosed are methods and devices for the construction and use of planar artificial fractures in EGS wells, including wells that contain both an injection and extraction points.

IPC Classes  ?

• F24J 3/08 - using geothermal heat (devices for producing mechanical power from geothermal energy F03G 4/00)

Abstract

A disclosed chemical detection system for detecting a target material, such as an explosive material, can include a cantilevered probe, a probe heater coupled to the cantilevered probe, and a piezoelectric element disposed on the cantilevered probe. The piezoelectric element can be configured as a detector and/or an actuator. Detection can include, for example, detecting a movement of the cantilevered probe or a property of the cantilevered probe. The movement or a change in the property of the cantilevered probe can occur, for example, by adsorption of the target material, desorption of the target material, reaction of the target material and/or phase change of the target material. Examples of detectable movements and properties include temperature shifts, impedance shifts, and resonant frequency shifts of the cantilevered probe. The overall chemical detection system can be incorporated, for example, into a handheld explosive material detection system.

IPC Classes  ?

• G01N 33/22 - FuelsExplosives
• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 25/00 - Investigating or analysing materials by the use of thermal means
• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
• G01N 29/02 - Analysing fluids

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Disclosed herein are a compression device and system which includes one or more sensors, such as piezoelectric sensors, thereby allowing dynamic monitoring of the applied pressure. A user and/or healthcare provider is able to ensure correct garment pressure at application, and dynamically monitor pressure, such as via a wireless communication system. The disclosed devices and system can be used for compression therapy, including to treat a subject afflicted with or at risk to develop venous stasis or lymphedema.

IPC Classes  ?

• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• H04M 1/725 - Cordless telephones

Abstract

Disclosed are systems and methods of continuous hydrothermal carbonization of wet biomass, such as manure. A disclosed system uses both inlet flow rate and outlet flow rate simultaneously to regulate the reaction time for continuous production.

IPC Classes  ?

• C02F 11/18 - Treatment of sludgeDevices therefor by thermal conditioning
• C02F 11/10 - Treatment of sludgeDevices therefor by pyrolysis

Abstract

Disclosed herein are methods of altering tissue succulence in plants. In some examples, a disclosed method includes overexpressing a modified helix-loop-helix transcription factor CEB1 in a plant cell, thereby altering plant succulence. The disclosed methods can be used to improve the drought and salinity tolerance of plants, such as in plants in arid or saline environments, and also enhance the ability of plants to perform. Also disclosed are CEB1 nucleic acids and transgenic plants containing such nucleic acids.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Abstract

Disclosed herein are support column structures which can be used to support bridges, buildings or other structures. In some cases, a support column structure can be deconstructable and include one or more removable elements. In some cases, a support column structure can include shape memory alloy reinforcing bars. In some cases, a removable element of a support column structure can include an engineered cementitious composite. In some cases, a removable element includes one or more sleeves to separate an engineered cementitious composite from one or more shape memory alloy reinforcing bars. Methods include assembling and disassembling a support column structure.

IPC Classes  ?

• E04C 3/34 - ColumnsPillarsStruts of concrete or other stone-like material, with or without permanent form elements, with or without internal or external reinforcement, e.g. metal coverings
• E04H 12/34 - Arrangements for erecting or lowering towers, masts, poles, chimney stacks, or the like
• E02D 27/01 - Flat foundations
• E02D 27/42 - Foundations for poles, masts, or chimneys
• E04C 3/36 - ColumnsPillarsStruts of materials not covered by groups or ColumnsPillarsStruts of a combination of two or more materials

Abstract

In particular embodiments, the present disclosure provides targets including a metal layer and defining a hollow inner surface. The hollow inner surface has an internal apex. The distance between at least two opposing points of the internal apex is less than about 15 μm. In particular examples, the distance is less than about 1 μm. Particular implementations of the targets are free standing. The targets have a number of disclosed shaped, including cones, pyramids, hemispheres, and capped structures. The present disclosure also provides arrays of such targets. Also provided are methods of forming targets, such as the disclosed targets, using lithographic techniques, such as photolithographic techniques. In particular examples, a target mold is formed from a silicon wafer and then one or more sides of the mold are coated with a target material, such as one or more metals.

IPC Classes  ?

• H05H 1/24 - Generating plasma
• H05G 2/00 - Apparatus or processes specially adapted for producing X-rays, not involving X-ray tubes, e.g. involving generation of a plasma

Abstract

Methods of labeling, identifying and differentiating microorganisms using functionalized Buckyballs are provided herein. The invention further provides methods for imaging or inhibiting gene expression using functionalized Buckyballs of the invention. The invention also provides a system for labeling, identifying and differentiating microorganisms.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Innovations for interactive computer displays (e.g., virtual reality systems) are presented. Motion sensor data is obtained from a motion sensor mounted to a user' s head. The motion sensor data is analyzed to determine user movement. A display is updated based on the user movement and output to a display device. Particular embodiments enable a user's natural movement styles to create movement in a virtual reality environment in a highly immersive manner. Further, certain embodiments allow for the user to walk in place (or run in place) and translate that motion into suitable, realistic virtual velocity values for use in a VR environment.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06F 3/0346 - Pointing devices displaced or positioned by the userAccessories therefor with detection of the device orientation or free movement in a 3D space, e.g. 3D mice, 6-DOF [six degrees of freedom] pointers using gyroscopes, accelerometers or tilt-sensors

Abstract

Disclosed herein are embodiments of composites and compositions that can be used for therapeutic applications in vivo and/or in vitro. The disclosed composites can comprise cores having magnetic nanoparticles, quantum dots, or combinations thereof and zwitterionic polymeric coatings that facilitate solubility and bioconjugation. The compositions disclosed herein can comprise the composites and one or more biomolecules, drugs, or combinations thereof. Also disclosed herein are methods of making the composites, composite components, and methods of making quantum dots for use in the composites.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

Disclosed herein are methods of inducing sperm deformation. In certain embodiments, the method includes contacting a sperm with an effective amount of triptonide, thereby inhibiting sperm motility. Also disclosed herein are methods of contraception. In certain embodiments, the method includes administering an effective amount of triptonide to a male subject for a sufficient period of time to cause sperm deformation, which are incompatible with fertilization, thus preventing pregnancy. In certain embodiments, the methods of contraception of the invention are reversible after a time period from treatment discontinuation.

IPC Classes  ?

• A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• A61K 31/365 - Lactones
• A61P 15/16 - Masculine contraceptives
• C07D 307/77 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems

Abstract

Non-invasive methods are provided herein for diagnosing samples as including a fungus, including fungal infection or contamination, with specific monoclonal antibodies capable of detecting molecules associated with fungi in the sample, such as a biological or environmental sample. These molecules can be identified using various methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), or a lateral flow immunoassay.

IPC Classes  ?

• C07K 16/14 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from fungi, algae or lichens
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Disclosed herein are embodiments of systems and methods for making silicon substrates. The disclosed systems use a unique combination of induction heating and crucible materials to produce silicon substrates in short time periods. The disclosed methods are cost-efficient and time-efficient and can be used to obtain pure silicon substrates having a desirable thinness for commercial use.

IPC Classes  ?

• C30B 11/00 - Single-crystal-growth by normal freezing or freezing under temperature gradient, e.g. Bridgman- Stockbarger method
• C30B 29/06 - Silicon

Abstract

Disclosed herein are embodiments of multicyclic compounds and methods of making such compounds. The disclosed methods reduce step-counts in the synthesis of complex targets, while reducing costs and waste streams.

IPC Classes  ?

• C07C 45/69 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by isomerisationPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to carbon-to-carbon double or triple bonds
• C07C 49/597 - Unsaturated compounds containing a keto group being part of a ring of a five-membered ring
• C07C 13/48 - Completely or partially hydrogenated naphthalenes
• C07C 13/547 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings at least one ring not being six-membered, the other rings being at the most six-membered

Abstract

Disclosed herein are embodiments of chalcogenide materials and chalcogenide-based materials that exhibit improved light-driven properties and performance in comparison to conventional materials. Also disclosed herein are embodiments of cost- and time-efficient methods of making such materials.

IPC Classes  ?

• C01G 21/21 - Sulfides
• C01B 19/00 - SeleniumTelluriumCompounds thereof
• C01G 11/02 - Sulfides
• G11C 13/02 - Digital stores characterised by the use of storage elements not covered by groups , , or using elements whose operation depends upon chemical change
• H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof

Abstract

Disclosed herein are embodiments of aryl compounds and polymers thereof that are made using methods that do not require harsh conditions or expensive reagents. The methods disclosed herein utilize precursor compounds that can be polymerized to form polycyclic aromatic hydrocarbons and polymers, such as carbon-based polymers like nanostructures (e.g., graphene or graphene-like nanoribbons).

IPC Classes  ?

• C07D 333/18 - Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C07C 43/235 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring, other than a six-membered aromatic ring

Abstract

Disclosed herein are support column structures which can be used to support bridges, buildings or other structures. In some cases, a support column structure can be deconstructable and include one or more removable elements. In some cases, a support column structure can include shape memory alloy reinforcing bars. In some cases, a removable element of a support column structure can include an engineered cementitious composite. In some cases, a removable element includes one or more sleeves to separate an engineered cementitious composite from one or more shape memory alloy reinforcing bars. Methods include assembling and disassembling a support column structure.

IPC Classes  ?

• E04C 3/34 - ColumnsPillarsStruts of concrete or other stone-like material, with or without permanent form elements, with or without internal or external reinforcement, e.g. metal coverings
• E02D 27/01 - Flat foundations
• E02D 27/42 - Foundations for poles, masts, or chimneys
• E04C 3/36 - ColumnsPillarsStruts of materials not covered by groups or ColumnsPillarsStruts of a combination of two or more materials
• E01D 19/02 - PiersAbutments

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present disclosure concerns embodiments of a catalyst system, such as a mixed catalyst composition, that can be used to make biofuel. In some embodiments, the mixed catalyst composition can comprise an inorganic catalyst and an organic catalyst, such as a cyclic organic catalyst. In particular disclosed embodiments, a mixed catalyst composition comprising, consisting essentially of, or consisting of an inorganic catalyst and an organic catalyst can be used to enhance the production of biofuel, such as biodiesel, by reducing the amount of time needed to make the biofuel as compared to that needed for the inorganic catalyst or the organic catalyst independently. Also disclosed herein are combinations and kits comprising, consisting essentially of, or consisting of embodiments of a mixed catalyst composition.

IPC Classes  ?

• C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis
• C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 23/04 - Alkali metals
• C10L 1/12 - Inorganic compounds
• C10L 1/233 - Organic compounds containing nitrogen containing nitrogen in a heterocyclic ring containing nitrogen and oxygen in the ring, e.g. oxazoles

Abstract

In one embodiment, the present disclosure provides a target or mold having one or more support arms coupled to a substrate. The support arm can be used in handling or positioning a target. In another embodiment, the present disclosure provides target molds, targets produced using such molds, and a method for producing the targets and molds. In various implementations, the targets are formed in a number of disclosed shapes, including a funnel cone, a funnel cone having an extended neck, those having Gaussian-profile, a cup, a target having embedded metal slugs, metal dotted foils, wedges, metal stacks, a Winston collector having a hemispherical apex, and a Winston collector having an apex aperture. In yet another embodiment, the present disclosure provides a target mounting and alignment system.

IPC Classes  ?

• H05H 6/00 - Targets for producing nuclear reactions
• B25J 11/00 - Manipulators not otherwise provided for
• F16M 13/02 - Other supports for positioning apparatus or articlesMeans for steadying hand-held apparatus or articles for supporting on, or attaching to, an object, e.g. tree, gate, window-frame, cycle
• H05G 2/00 - Apparatus or processes specially adapted for producing X-rays, not involving X-ray tubes, e.g. involving generation of a plasma
• H05H 1/46 - Generating plasma using applied electromagnetic fields, e.g. high frequency or microwave energy
• H01J 40/16 - Photoelectric discharge tubes not involving the ionisation of a gas having photo-emissive cathode, e.g. alkaline photoelectric cell

Abstract

2; and 3) an optional regeneration reactor reoxygenating oxygen carrier from the first two reactors which is returned to the fuel reactor. The feedback control system comprises an accumulator and controllable elements to apportion oxygen carrier between fuel and burn-off reactors and extract oxygen carrier and heavy ash. This ash and ash from the regenerator products are sold or disposed.

IPC Classes  ?

• F23C 10/22 - Fuel feeders specially adapted for fluidised bed combustion apparatus

Abstract

Disclosed herein are methods of treating and diagnosing muscular dystrophy. In some examples, the methods include treating muscular dystrophy by administering to the subject a therapeutically effective amount of an agent that alters the expression of at least one miR gene product, such as miRNA-124 and/or miRNA-29 thereby treating muscular dystrophy. In one particular example, the method of treatment includes administering an agent that decreases the expression or activity of miRNA-124. In another embodiment, the method of treatment includes administering a composition that includes one or more agents to decrease the expression and/or activity of miRNA-124 and one or more agents to alter the activity of miRNA-29 (increase or decrease). Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 38/05 - Dipeptides
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/404 - Indoles, e.g. pindolol

Abstract

A disclosed chemical detection system for detecting a target material, such as an explosive material, can include a cantilevered probe, a probe heater coupled to the cantilevered probe, and a piezoelectric element disposed on the cantilevered probe. The piezoelectric element can be configured as a detector and/or an actuator. Detection can include, for example, detecting a movement of the cantilevered probe or a property of the cantilevered probe. The movement or a change in the property of the cantilevered probe can occur, for example, by adsorption of the target material, desorption of the target material, reaction of the target material and/or phase change of the target material. Examples of detectable movements and properties include temperature shifts, impedance shifts, and resonant frequency shifts of the cantilevered probe. The overall chemical detection system can be incorporated, for example, into a handheld explosive material detection system.

IPC Classes  ?

• G01N 25/48 - Investigating or analysing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
• G01N 33/22 - FuelsExplosives
• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 25/00 - Investigating or analysing materials by the use of thermal means
• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
• G01N 29/02 - Analysing fluids

Abstract

B. pseudomallei, such as meliodosis.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/554 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/536 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase

Abstract

7) pyrochlore nanorod. The method of synthesizing the pyrochlore nanorod is template-free.

IPC Classes  ?

• B01J 23/18 - Arsenic, antimony or bismuth
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C01G 29/00 - Compounds of bismuth

Abstract

The invention provides a chemical detection system for detecting at least one target chemical species, including a self-sensed cantilevered probe array having a plurality of self-sensed cantilevered probes, at least one chemical-sensitive coating material applied to at least one cantilevered probe in the cantilevered probe array, and an interface circuit that is coupled to the cantilevered probe array. At least one cantilevered probe in the cantilevered probe array exhibits a shifted cantilevered probe response when the cantilevered probe array is exposed to the target chemical species and the interface circuit actuates the cantilevered probe. A handheld chemical detection system and a method of operation are also disclosed.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 29/02 - Analysing fluids
• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01N 29/44 - Processing the detected response signal
• G01N 29/46 - Processing the detected response signal by spectral analysis, e.g. Fourier analysis

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• C07D 209/04 - IndolesHydrogenated indoles

Abstract

Disclosed herein are methods of inhibiting sperm motility. In some embodiments, a method of inhibiting sperm motility includes contacting a sperm with an effective amount of 3BP, thereby inhibiting sperm motility. Also disclosed herein are methods of contraception. In some embodiments, a method of contraception includes administering an effective amount of 3BP to the vagina so that sperm in contact with 3BP change their swimming patterns, which are incompatible with fertilization, thus preventing pregnancy. In one embodiment, a method includes topical application of 3BP to the penis in an amount effective to cause complete loss of motility of ejaculated sperm during sexual intercourse, thereby achieving contraception. In some examples, 3BP is administered as a spermicide in the forms of a jelly (gel), films, sponges, foams and timed-release mesh. In some examples, condoms are coated with 3BP-containing lubricant to achieve contraception.

IPC Classes  ?

• A61P 15/16 - Masculine contraceptives

Abstract

A disclosed chemical detection system for detecting a target material, such as an explosive material, can include a cantilevered probe, a probe heater coupled to the cantilevered probe, and a piezoelectric element disposed on the cantilevered probe. The piezoelectric element can be configured as a detector and/or an actuator. Detection can include, for example, detecting a movement of the cantilevered probe or a property of the cantilevered probe. The movement or a change in the property of the cantilevered probe can occur, for example, by adsorption of the target material, desorption of the target material, reaction of the target material and/or phase change of the target material. Examples of detectable movements and properties include temperature shifts, impedance shifts, and resonant frequency shifts of the cantilevered probe. The overall chemical detection system can be incorporated, for example, into a handheld explosive material detection system.

IPC Classes  ?

• G01Q 70/08 - Probe characteristics

Abstract

Disclosed herein are a7ß1 integrin modulatory agents and methods of using such to treat conditions associated with decreased a7ß1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an a7ß1 integrin modulatory agent to the subject with muscular dystrophy, wherein the a7ß1 integrin modulatory agent increases a7ß1 integrin expression or activity as compared to a7ß1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing a7ß1 integrin expression by use of the disclosed a7ß1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Among other aspects, the present disclosure provides a computer implemented method of routing information. A first routing information base is received at a proxy router. The first proxy router compares the first routing information based with a second routing information base associated with an assisted router. The proxy router updates the second routing information base based on the first routing information base. The proxy routing transmits updated routing information to the assisted router.

IPC Classes  ?

• G06F 15/173 - Interprocessor communication using an interconnection network, e.g. matrix, shuffle, pyramid, star or snowflake
• H04L 12/751 - Topology update or discovery
• H04L 12/703 - Route fault prevention or recovery, e.g. rerouting, route redundancy, virtual router redundancy protocol [VRRP] or hot standby router protocol [HSRP]
• H04L 29/08 - Transmission control procedure, e.g. data link level control procedure

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
• A61K 31/415 - 1,2-Diazoles
• A61K 38/05 - Dipeptides
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings

Abstract

Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

IPC Classes  ?

• A61K 31/33 - Heterocyclic compounds
• A61K 31/38 - Heterocyclic compounds having sulfur as a ring hetero atom
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular dystrophy. Provided are methods of enhancing muscle regeneration, repair, or maintenance in a subject by administering galectin, such as Galectin-1 and/or Galectin-3 to a subject in need thereof. Also disclosed are methods of increasing or maintaining muscle strength and/or bone density in a subject by administering an effective amount of a Galectin-1 composition, Galectin-3 composition or a combination thereof to the subject in need thereof. Methods of preventing, inhibiting and/or reducing muscle loss and/or bone loss in a subject by administering an effective amount of a Galectin-1 composition, Galectin-3 composition or a combination thereof to the subject in need thereof are disclosed.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to two dimensional polymers and methods of making the same. Irradiation of polycyclic, three bladed monomers, such as polyaromatic, three bladed monomers or an antrip monomer, derivatives or analogs thereof, with ultraviolet radiation provides the two dimensional polymers, which may be used in membrane applications.

IPC Classes  ?

• C08F 32/00 - Homopolymers or copolymers of cyclic compounds having no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system
• C08G 61/02 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes
• C08G 61/10 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aromatic carbon atoms, e.g. polyphenylenes

Abstract

B. pseudomallei, such as meliodosis.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/554 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A superadiabatic burner has a flame holder formed from a porous medium, a fuel inlet coupled to the flame holder, a fuel outlet coupled to the flame holder, a preheater comprising an inlet and an outlet coupled to the fuel inlet, and a radiating rod coupled to the porous medium. The porous medium comprises a first porous section and a second porous section. Methods of using the burner allow preheated air or other mixtures to be provided to the fuel inlet as part of a fuel air mixture for the burner.

IPC Classes  ?

• F23D 14/16 - Radiant burners using permeable blocks
• F23D 14/66 - Preheating the combustion air or gas

Abstract

Disclosed herein are methods, kits and systems for signal amplification that can be used for many analytes. For example, a method of detecting an analyte in a sample includes contacting the sample containing the analyte with a detecting agent, wherein the detecting agent contains a specific binding agent that binds the analyte and zinc nanoparticles wherein the zinc nanoparticles and specific binding agent are coupled together; exposing the analyte bound to the specific binding agent which is coupled to the zinc nanoparticles to an acidic condition to release zinc ions from the zinc nanoparticles; contacting the released zinc ions with an indicator to generate a signal; and detecting the signal. The disclosed bioassay can be used in clinical and non-clinical settings. For example, the method can be used for clinical diagnosis, prognosis, and/or treatment-effectiveness or for testing for the presence of a substance like biological or chemical agents.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids